NEW DELHI (Reuters) -India's pharmaceutical exports this fiscal year are set to grow nearly twice as fast as last year to hit sales of $27 billion, driven by strong U.S. buying, a government-backed trade body told Reuters, despite deaths linked to Indian-made cough syrups. The robust forecast comes against the backdrop of earlier concerns from the government that last year's deaths of dozens of children in Gambia, which the World Health Organization (WHO) linked to drugs made in India, had "adversely impacted the image of India's pharmaceutical products across the globe". Two other cough syrups made in India killed 19 children in Uzbekistan around December, according to the Uzbekistan government.
Pharmaceuticals Export Promotion Council Of India: The robust forecast comes against the backdrop of earlier concerns from the government that last year s deaths of dozens of children in Gambia, which the World Health Organization (WHO) linked to drugs made in India, had "adversely impacted the image of India s pharmaceutical products across the globe".
India s pharmaceutical exports are predicted to reach $27bn this fiscal year, boosted by strong US demand, despite concern over Indian-made cough syrups previously linked to scores of children s deaths. The robust forecast follows worries from the Indian government over dwindling global confidence in the quality of the country s pharma exports following the incidents in Gambia and Uzbekistan.
India s pharmaceutical
exports this fiscal year are set to grow nearly twice as fast as
last year to hit sales of $27 billion, driven by strong U.S.
buying, a government-backed trade body told.
The robust forecast comes against the backdrop of earlier concerns from the government that last year s deaths of dozens of children in Gambia, which the World Health Organization (WHO) linked to drugs made in India, had